Premium
Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease
Author(s) -
Imai Y.,
Dobrian A. D.,
Weaver J. R.,
Butcher M. J.,
Cole B. K.,
Galkina E. V.,
Morris M. A.,
TaylorFishwick D. A.,
Nadler J. L.
Publication year - 2013
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12161
Subject(s) - insulin resistance , inflammation , nicotinamide adenine dinucleotide phosphate , islet , diabetes mellitus , endocrinology , medicine , adipose tissue , type 2 diabetes , immune system , nadph oxidase , biology , immunology , oxidative stress , oxidase test , biochemistry , enzyme
Inflammation is an established pathogenic player in insulin resistance, islet demise and atherosclerosis. The complex interactions between cytokines, immune cells and affected tissues result in sustained inflammation in diabetes and atherosclerosis. 12‐ and 15‐lipoxygenase ( LO ), such as 12/15‐ LO , produces a variety of metabolites through peroxidation of fatty acids and potentially contributes to the complex molecular crosstalk at the site of inflammation. 12‐ and 15‐ LO pathways are frequently activated in tissues affected by diabetes and atherosclerosis including adipose tissue ( AT ), islets and the vasculature. Moreover, mice with whole body and tissue‐specific knockout of 12/15‐ LO are protected against insulin resistance, hyperglycaemia and atherosclerosis supporting functional contribution of 12‐ and 15‐ LO pathways in diabetes and atherosclerosis. Recently, it has emerged that there is a temporal regulation of the particular isoforms of 12‐ and 15‐ LO in human AT and islets during the development of type 1 and type 2 diabetes and obesity. Analyses of tissues affected by diabetes and atherosclerosis also implied the roles of interleukin ( IL )‐12 and nicotinamide adenine dinucleotide phosphate ( NADPH ) oxidase‐1 ( NOX‐1 ) in islets and IL‐17A in atherosclerosis. Future studies should aim to test the efficacy of inhibitions of these mediators for treatment of diabetes and atherosclerosis.